Based on evidence from several clinical trials, an FDA advisory committee has voted unanimously to recommend the approval of a cannabis-based oral solution for the treatment of 2 rare forms of epilepsy.
MORE EXCLUSIVES »
If health care providers are aware that having an identified cause of epilepsy is associated with poor response to treatment, appropriate counseling and management strategies can be established.
In a recent systematic review, researchers evaluated data from 36 studies regarding the safety, efficacy, and tolerability of pharmaceutical-grade cannabidiol for the treatment of drug-resistant epilepsy in children.
The US Food and Drug Administration has recently approved a new smart watch that can monitor seizure activity and alert caregivers.